

## **Product datasheet for TR306641**

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **Apolipoprotein A V (APOA5) Human shRNA Plasmid Kit (Locus ID 116519)**

**Product data:** 

**Product Type:** shRNA Plasmids

**Product Name:** Apolipoprotein A V (APOA5) Human shRNA Plasmid Kit (Locus ID 116519)

**Locus ID:** 116519

**Synonyms:** APOAV; RAP3

Vector: pRS (TR20003)

E. coli Selection: Ampicillin

Mammalian Cell Puromycin

Selection:

Fulbiliycili

Format: Retroviral plasmids

Components: APOA5 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID =

116519). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.

**RefSeq:** NM 001166598, NM 052968, NM 052968.1, NM 052968.2, NM 052968.3, NM 052968.4,

NM 001166598.1, BC101787, BC101787.1, BC101789, NM 052968.5, NM 001166598.2

UniProt ID: Q6Q788

Summary: The protein encoded by this gene is an apolipoprotein that plays an important role in

regulating the plasma triglyceride levels, a major risk factor for coronary artery disease. It is a

component of high density lipoprotein and is highly similar to a rat protein that is

upregulated in response to liver injury. Mutations in this gene have been associated with hypertriglyceridemia and hyperlipoproteinemia type 5. This gene is located proximal to the apolipoprotein gene cluster on chromosome 11q23. Alternatively spliced transcript variants

encoding the same protein have been identified. [provided by RefSeq, Oct 2009]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).